These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Long-term treatment of severe cardiac insufficiency with captopril].
    Author: Ohayon J, Colle JP, Ledain L, Besse P.
    Journal: Ann Cardiol Angeiol (Paris); 1984; 33(4):239-44. PubMed ID: 6380382.
    Abstract:
    23 patients with a mean age of 62 +/- 7 years and suffering from a cardiomyopathy with severe chronic heart failure (16 patients in stage IV of the New York Association (NYHA) classification and 7 in stage III NYHA) received long term treatment with captopril (9 patients received 75 mg/day, 9 received 150 mg/day and 5 received 300 mg/day) with a follow-up of 12 +/- 9 months. Following the acute administration of captopril, there was an increase in the cardiac index (Cl) (2.76 +/- 0.56 vs 2.10 +/- 0.4 l . min-1 . m-2, p less than 0.001) between the 4th and 6th hour, a significant decrease in peripheral resistance (PR) (1416 +/- 304 vs 1094 +/- 406 dynes/s/cm-5, p less than 0.001), total pulmonary resistance (TPR) (537 +/- 228 vs 660 +/- 258 dynes/s/cm-5, p less than 0.01) and pulmonary diastolic pressure (PDP) (15.4 +/- 7.2 vs 18.6 +/- mm Hg, p less than 0.001). An early (3rd day) and reversible renal failure caused the treatment to be suspended in one patient. In the 22 other patients, a marked and lasting clinical improvement was obtained (18 patients with stage II NYHA and 4 with stage III NYHA). The beneficial haemodynamic effects persisted until the 4th month in 14 patients (Cl: 2.38 +/- 0.4 vs 2.10 +/- 0.4 l . min-1 . m-2, p less than 0.1; PR: 1828 +/- 314 vs 2054 +/- 406 dynes/s/cm-5, p less than 0.01; TPR: 526 +/- 284 vs 660 +/- 258 dynes/s/cm-5, p less than 0.01; PDP: 16.8 +/- 8.7 vs 18.6 +/- 8.6 mmHg, p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]